Drug intelligence / Profile preview

Nicofetamide

Development stage: Discontinued
Lead developer: Silag
Modality: Small Molecules

Overview

Nicofetamide is a synthetic small molecule drug classified as an antispasmodic and anticholinergic agent. Its mechanism of action involves antagonizing muscarinic acetylcholine receptors, leading to relaxation of smooth muscles. It was developed by Cilag and marketed under the brand name Lyspamin by Bracco. The monograph for Nicofetamide has been retired, indicating it is no longer actively revised or updated.

Brand names: Lyspamin
Other names: N-(1,2-Diphenylethyl)-3-pyridinecarboxamide1-nicotinylamino-1,2-diphenylethaneN-(1,2-diphenylethyl)nicotinamidelispaminaN-(1,2-diphenylethyl)pyridine-3-carboxamide

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Nicofetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicofetamide.

Explore the full profile